Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
56.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
September 21, 2023
Via
Benzinga
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
September 21, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Analyst Ratings for Travere Therapeutics
↗
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
↗
August 18, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
↗
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Expert Ratings for Travere Therapeutics
↗
July 18, 2023
Via
Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
↗
September 19, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
↗
September 08, 2023
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.
Via
Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
September 05, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Travere Therapeutics
↗
June 07, 2023
Via
Benzinga
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
↗
August 10, 2023
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Small-Cap Stocks That Could Be Big-Time Winners
↗
July 22, 2023
These stocks come with significant risks. But they could generate huge returns over time.
Via
The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
↗
July 21, 2023
Travere Therapeutics shares have lost nearly 30% since early May.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
↗
July 21, 2023
Via
Benzinga
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 20, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
↗
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 17, 2023
Via
Benzinga
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
July 17, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
↗
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
↗
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
